References of "2008"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailExpression profiling of senescent-associated genes in human dermis from young and old donors. Proof-of-concept study.
Borlon, Celine; Weemaels, Geoffroy; Godard, Patrice et al

in Biogerontology (2008), 9(3), 197-208

It is often described that it is difficult to really discriminate the cause of intrinsic skin aging. The aim of this study was to compare the profiles of expression of senescence-associated genes in ... [more ▼]

It is often described that it is difficult to really discriminate the cause of intrinsic skin aging. The aim of this study was to compare the profiles of expression of senescence-associated genes in biopsies of dermis from young and old human donors. TGF-beta1 was up-regulated in the dermis of old donors as well as the TGF-beta1-regulated genes. The anti-oxidant enzymes Selenium-dependent Glutathione peroxidase and Glutatione S-Transferase Theta 1 were also up-regulated in old dermis as well as Tumor Necrosis Factor Receptor Superfamily 1A. None of these genes had altered expression level in skin fibroblasts embedded in a collagen matrix and exposed to sublethal doses of UVB, suggesting their involvement in intrinsic aging. This study represents a proof-of-concept of larger whole transcriptome studies where all avenues should be used to subtract changes in gene expression due to extrinsic aging from changes potentially due to intrinsic aging. [less ▲]

Detailed reference viewed: 35 (1 ULg)
See detailA quoi tient le succès des interventions ?
Pichault, François ULg

in Vrancken, Didier; Dubois, Christophe; Schoenaers, Frédéric (Eds.) Penser la négociation. Mélanges en hommage à Olgierd Kut (2008)

Proposes a conceptual framework concerning the key success factors of action researches in organizations, based on the way in which the relations with the client are negotiated

Detailed reference viewed: 56 (20 ULg)
Full Text
See detailHet zoekgeraakte bijproduct. Over literaire prijzen
Spinoy, Erik ULg

in Freespace Nieuwzuid (2008), 8(32), 6-23

This article reflects on the growing importance of literary prizes, while other literary institutions are rapidly losing ground and influence.

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailMajor clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
Emery, Sean; Neuhaus, Jacqueline A; Phillips, Andrew N et al

in Journal of Infectious Diseases (2008), 197(8), 1133-44

BACKGROUND: The SMART study randomized 5,472 human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts >350 cells/microL to intermittent antiretroviral therapy (ART; the drug conservation ... [more ▼]

BACKGROUND: The SMART study randomized 5,472 human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts >350 cells/microL to intermittent antiretroviral therapy (ART; the drug conservation [DC] group) versus continuous ART (the viral suppression [VS] group). In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART. METHODS: Patients who were either ART naive (n=249) or who had not been receiving ART for >or= 6 months (n=228) were analyzed. The following clinical outcomes were assessed: (i) opportunistic disease (OD) or death from any cause (OD/death); (ii) OD (fatal or nonfatal); (iii) serious non-AIDS events (cardiovascular, renal, and hepatic disease plus non-AIDS-defining cancers) and non-OD deaths; and (iv) the composite of outcomes (ii) and (iii). RESULTS: A total of 477 participants (228 in the DC group and 249 in the VS group) were followed (mean, 18 months). For outcome (iv), 21 and 6 events occurred in the DC (7 in ART-naive participants and 14 in those who had not received ART for >or= 6 months) and VS (2 in ART-naive participants and 4 in those who had not received ART for 6 months) groups, respectively. Hazard ratios for DC vs. VS by outcome category were as follows: outcome (i), 3.47 (95% confidence interval [CI], 1.26-9.56; p=.02); outcome (ii), 3.26 (95% CI, 1.04-10.25; p=.04); outcome (iii), 7.02 (95% CI, 1.57-31.38; p=.01); and outcome (iv), 4.19 (95% CI, 1.69-10.39; p=.002 ). CONCLUSIONS: Initiation of ART at CD4+ cell counts >350 cells/microL compared with <250 cells/microL may reduce both OD and serious non-AIDS events. These findings require validation in a large, randomized clinical trial. [less ▲]

Detailed reference viewed: 196 (1 ULg)
Full Text
Peer Reviewed
See detailTARC and IL-5 expression correlates with tissue eosinophilia in peripheral T-cell lymphomas.
Thielen, Caroline ULg; Radermacher, Vincent ULg; Trimeche, Mounir et al

in Leukemia Research (2008), 32(9), 1431-8

The current study attempts to characterize the eosinophilia associated with T-cell lymphomas and to investigate its possible relationship with the secretion of eosinophil-stimulating factors by lymphoma ... [more ▼]

The current study attempts to characterize the eosinophilia associated with T-cell lymphomas and to investigate its possible relationship with the secretion of eosinophil-stimulating factors by lymphoma cells and/or intra-tumoral surrounding cells. Paraffin-embedded specimens from 50 patients diagnosed with peripheral T-cell lymphomas, either unspecified (PTCL-U, n=30) or angioimmunoblastic (AITL, n=20) were morphologically assessed for intra-tumoral eosinophilia and analyzed by immunohistochemistry using specific antibodies directed against TARC, IL-5, RANTES, and eotaxin. The AITL and PTCL-U cases contained a mean of 147+/-41 and 102+/-37 eosinophils per 10 high power fields, respectively. Thirty-two of 47 cases (68%) showed IL-5-positive lymphoma cells while 15/50 (30%) tumors showed variable staining for TARC in scattered non-lymphoid cells with dendritic morphology. TARC and IL-5-positive cases possessed significantly more eosinophils. Our data indicate that IL-5 and TARC expression highly correlate with eosinophilia in T-cell lymphomas, suggesting that these chemokines are involved in the recruitment of eosinophils into the tumors. [less ▲]

Detailed reference viewed: 30 (3 ULg)
Full Text
Peer Reviewed
See detailUnknown placental glycoprotein J2-45 kDa [Fragment] from Bison bonasus placenta - Access number P85329
Kiewisz, J.; Melo de Sousa, Noelita ULg; Beckers, Jean-François ULg et al

E-print/Working paper (2008)

N-terminal microsequence obtained after purification and characterization of placental proteins in Bison bonasus. Proteins were submitted to SwissProt databank.

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailQuantum imaging with uncorrelated single photon sources
Bastin, Thierry ULg

in Proceedings of SPIE (2008)

We propose a technique to obtain sub-wavelength resolution using photons from uncorrelated single photon sources. The method employs N photons of wavelength λ spontaneously emitted from N atoms and ... [more ▼]

We propose a technique to obtain sub-wavelength resolution using photons from uncorrelated single photon sources. The method employs N photons of wavelength λ spontaneously emitted from N atoms and subsequently detected by N detectors. We demonstrate that for certain detector positions the N-th order correlation function as a function of the first detector position is a pure sinusoidal oscillation with a fringe spacing of λ/N and a contrast of 100%. The result corresponds to an N-fold increase in resolution compared to classical microscopy. Our technique is also capable of imaging a distinct physical object with sub-Rayleigh resolution. [less ▲]

Detailed reference viewed: 24 (4 ULg)
Full Text
Peer Reviewed
See detailPrevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.
Vercauteren, Jurgen; Derdelinckx, Inge; Sasse, Andre et al

in AIDS Research and Human Retroviruses (2008), 24(3), 355-62

This study is the first prospective study to assess the prevalence, epidemiology, and risk factors of HIV-1 drug resistance in newly diagnosed HIV-infected patients in Belgium. In January 2003 it was ... [more ▼]

This study is the first prospective study to assess the prevalence, epidemiology, and risk factors of HIV-1 drug resistance in newly diagnosed HIV-infected patients in Belgium. In January 2003 it was initiated as part of the pan-European SPREAD program, and continued thereafter for four inclusion rounds until December 2006. Epidemiological, clinical, and behavioral data were collected using a standardized questionnaire and genotypic resistance testing was done on a sample taken within 6 months of diagnosis. Two hundred and eighty-five patients were included. The overall prevalence of transmitted HIV-1 drug resistance in Belgium was 9.5% (27/285, 95% CI: 6.6-13.4). Being infected in Belgium, which largely coincided with harboring a subtype B virus, was found to be significantly associated with transmission of drug resistance. The relatively high rate of baseline resistance might jeopardize the success of first line treatment as more than 1 out of 10 (30/285, 10.5%) viruses did not score as fully susceptible to one of the recommended first-line regimens, i.e., zidovudine, lamivudine, and efavirenz. Our results support the implementation of genotypic resistance testing as a standard of care in all treatment-naive patients in Belgium. [less ▲]

Detailed reference viewed: 40 (4 ULg)
Full Text
Peer Reviewed
See detailSubgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper, David A; Steigbigel, Roy T; Gatell, Jose M et al

in New England Journal of Medicine [=NEJM] (2008), 359(4), 355-65

BACKGROUND: We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1 ... [more ▼]

BACKGROUND: We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with triple-class drug resistance and in whom antiretroviral therapy had failed. METHODS: We conducted subgroup analyses of the data from week 48 in both studies according to baseline prognostic factors. Genotyping of the integrase gene was performed in raltegravir recipients who had virologic failure. RESULTS: Virologic responses to raltegravir were consistently superior to responses to placebo, regardless of the baseline values of HIV-1 RNA level; CD4 cell count; genotypic or phenotypic sensitivity score; use or nonuse of darunavir, enfuvirtide, or both in optimized background therapy; or demographic characteristics. Among patients in the two studies combined who were using both enfuvirtide and darunavir for the first time, HIV-1 RNA levels of less than 50 copies per milliliter were achieved in 89% of raltegravir recipients and 68% of placebo recipients. HIV-1 RNA levels of less than 50 copies per milliliter were achieved in 69% and 80% of the raltegravir recipients and in 47% and 57% of the placebo recipients using either darunavir or enfuvirtide for the first time, respectively. At 48 weeks, 105 of the 462 raltegravir recipients (23%) had virologic failure. Genotyping was performed in 94 raltegravir recipients with virologic failure. Integrase mutations known to be associated with phenotypic resistance to raltegravir arose during treatment in 64 patients (68%). Forty-eight of these 64 patients (75%) had two or more resistance-associated mutations. CONCLUSIONS: When combined with an optimized background regimen in both studies, a consistently favorable treatment effect of raltegravir over placebo was shown in clinically relevant subgroups of patients, including those with baseline characteristics that typically predict a poor response to antiretroviral therapy: a high HIV-1 RNA level, low CD4 cell count, and low genotypic or phenotypic sensitivity score. (ClinicalTrials.gov numbers, NCT00293267 and NCT00293254.) [less ▲]

Detailed reference viewed: 38 (2 ULg)
Full Text
Peer Reviewed
See detailLes tumeurs de la sphere ORL: standards de traitement et nouvelles approches en radiotherapie.
Coucke, Philippe ULg; Piret, Pascal ULg; Werenne, Xavier ULg et al

in Revue Médicale de Liège (2008), 63(3), 141-8

We intend to review the general value of radiotherapy in the management of head and neck cancer. Our aim is to define a treatment protocol which is evidence-based and therefore of use in daily clinical ... [more ▼]

We intend to review the general value of radiotherapy in the management of head and neck cancer. Our aim is to define a treatment protocol which is evidence-based and therefore of use in daily clinical practice. There is general agreement on the efficacy of the concomitant schedules combining radiotherapy and chemotherapy, both in the adjuvant setting as well as in the exclusive non-surgical approach. This however does not preclude further research aiming at optimizing the therapeutic index. As far as neoadjuvant chemotherapy is concerned, applied prior to radical local treatment, there are no conclusive data available which allows us to implement this treatment option in routine clinical practice. This approach deserves further investigations and patients should be entered in well designed prospective randomized trials. [less ▲]

Detailed reference viewed: 148 (16 ULg)
Full Text
Peer Reviewed
See detailDecline of antibiotic use in primary care.
Frippiat, Frédéric ULg; Chandrikakumari, Kavitha; Moutschen, Michel ULg

in Lancet Infectious Diseases (2008), 8(5), 272273

Detailed reference viewed: 14 (3 ULg)
See detailLate Devonian plants from Australia: the anatomically preserved flora from Barraba, New South Wales.
Meyer-Berthaud, Brigitte; Blanchard, Romain; Decombeix, Anne-Laure et al

Conference (2008)

Detailed reference viewed: 19 (0 ULg)
See detailModulation of steroid action: Importance of steroid binding globulins
Charlier, Thierry ULg

Scientific conference (2008)

Detailed reference viewed: 5 (0 ULg)
See detailLes formules basées sur la créatinine :indiscutable ?
Delanaye, Pierre ULg

Conference given outside the academic context (2008)

Detailed reference viewed: 19 (2 ULg)
See detailLe problème lexical "en aines" à la lumière des exemples du Roman en prose de Guillaume d’Orange
Henrard, Nadine ULg

in Colombo Timelli, M.; Van Hemelryck, T. (Eds.) Quant l’ung amy pour l’autre veille : Mélanges de moyen français offerts à Claude Thiry (2008)

Révision du dossier de l’expression "en aines" à la lumière de sept occurrences offertes par le Roman en prose de Guillaume d’Orange, en justifiant d’abord des choix de lecture de l'édition du texte (éd ... [more ▼]

Révision du dossier de l’expression "en aines" à la lumière de sept occurrences offertes par le Roman en prose de Guillaume d’Orange, en justifiant d’abord des choix de lecture de l'édition du texte (éd. M. Tyssens, N. Henrard et L. Gemenne,Paris, Champion, 1999 et 2006) par rapport aux éditions anciennes et en mettant en évidence les difficultés posées par deux exemples tirés de la copie B (BnF fr. 796). En se fondant sur la connaissance de la langue du prosateur anonyme, sur l’usage des doublets synonymiques, sur le comportement du scribe B, on peut rattacher le terme à l’étymon hamus qui a produit l’a.fr. ain, haim ‘hameçon’. Estre en aisnes, expression figurée, peut qualifier « des amours précaires, qui demeurent en suspens », ou dans un contexte guerrier levé en aisnes (ex. 2, 3, 5), ‘désarçonné avant de retomber au sol’. (cf. Bulletin bibliographique de la Société Rencesvals, 40, 2008-2009, n°197) [less ▲]

Detailed reference viewed: 26 (2 ULg)
Full Text
Peer Reviewed
See detailLes vaccins contre la FCO protègent-ils le foetus?
Thiry, Etienne ULg

in Point Vétérinaire (2008), 287

Detailed reference viewed: 22 (1 ULg)
See detailDomaine public, domaine privé, biens des pouvoirs publics
Pâques, Michel ULg

Book published by Larcier (2008)

Detailed reference viewed: 216 (21 ULg)
See detailApproche isocinétique des blessures ischio-jambières : jusqu’à la prévention ?
Croisier, Jean-Louis ULg

in Abstract book du 5ème Clinic Pré-Sport Rencontres de Médecine du Sport : « Approche isocinétique des blessures ischio-jambières : jusqu’à la prévention ? » (2008)

Detailed reference viewed: 93 (12 ULg)